Company Filing History:
Years Active: 1999-2001
Title: Ahmed Adel Sakr: Innovator in Pharmaceutical Formulations
Introduction
Ahmed Adel Sakr is a notable inventor based in Cincinnati, OH (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled release formulations. With a total of 2 patents, his work focuses on improving therapeutic effects through innovative drug delivery systems.
Latest Patents
One of his latest patents is titled "Anionic exchange polymer complexes of buspirone." This invention describes a controlled release form of buspirone medicament, which comprises buspirone in intimate admixture with an anionic exchange polymer complexing agent. The components form a complex upon the addition of water, allowing for improved dosing of buspirone to achieve a more targeted therapeutic effect in patients. Another significant patent is "Oral formulation for treatment of bacteria-induced diseases of the colon." This invention is directed to lanthocin-containing tablet formulations for oral administration. The formulations are designed to deliver lanthocin to the colon in amounts sufficient to treat diseases caused by bacterial infections of the colon. Additionally, a process for the preparation of these formulations is provided.
Career Highlights
Ahmed has worked with reputable organizations, including the University of Cincinnati and American Pharmaceuticals International. His experience in these institutions has contributed to his expertise in pharmaceutical innovations.
Collaborations
Throughout his career, Ahmed has collaborated with notable individuals such as Walid Abdel-Azim Habib and Arthur H Goldberg. These collaborations have further enriched his work and contributions to the field.
Conclusion
Ahmed Adel Sakr is a distinguished inventor whose work in pharmaceutical formulations has the potential to significantly impact patient care. His innovative approaches to drug delivery systems demonstrate his commitment to advancing medical science.